DermTech receives positive medical coverage by Geisinger

 

• DermTech (NASDAQ:DMTK) has announced that Geisinger Health System has issued a positive medical benefit policy for its commercial and medicare business segment for the DermTech Pigmented Lesion Assay (“PLA”).
• DermTech’s PLA is the first non-invasive gene expression test for the early detection of melanoma. The PLA has a 99% negative predictive value.
• Per the policy, which closely mirrors the final local coverage determination by the Medicare Administrative Contractor, Palmetto GBA MolDx: Gene expression profiling for cutaneous melanoma utilizing the Pigmented Lesion Assay RNA gene expression test on skin samples obtained via adhesive patches is considered medically necessary on certain criterias.
• Using the PLA will enhance the early detection of melanoma sparing the patient the need for an invasive biopsy,” said Dan Visage, Senior Vice President of Payor Access for DermTech.
• DMTK +12.3% after hours to $31.48
• Press Release
• https://seekingalpha.com/news/3647809-dermtech-receives-positive-medical-coverage-geisinger